PMS TRAZODONE HCL TAB 50MG Strength
Active ingredient(s) See footnote 8 : Strength TRAZODONE HYDROCHLORIDE : 50 MG · DIN 01937227 · PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4
Health Canada status: MARKETED
What is PMS TRAZODONE HCL TAB 50MG?
PMS TRAZODONE HCL TAB 50MG Strength contains Active ingredient(s) See footnote 8 : Strength TRAZODONE HYDROCHLORIDE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 01937227, held by PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4, supplied as Tablet for Oral administration. Health Canada currently lists it as marketed, status dated 31-Dec-1993. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS TRAZODONE HCL TAB 50MG used for?
Symptomatic relief of depressive illness.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01937227 |
|---|---|
| Brand name | PMS TRAZODONE HCL TAB 50MG |
| Generic / active ingredient | Active ingredient(s) See footnote 8 : Strength TRAZODONE HYDROCHLORIDE : 50 MG |
| Manufacturer | PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 |
| Strength | Strength |
| Dosage form | Tablet |
| Route of administration | Oral |
| Schedule | PRESCRIPTION |
| ATC code | N06AX05 TRAZODONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1993 |
| Original market date | 1993-12-31 |
How is it administered?
Initiate at low dose and increase gradually. Take after a meal or light snack. Initial adult dose: 150 mg/day in divided doses. Max: 400 mg/day (outpatients) or 600 mg/day (inpatients).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (standard section header present but content truncated).
How is it supplied?
Not explicitly detailed in the provided text (mentions 50 mg, 75 mg, and 100 mg strengths).
Contraindications
Hypersensitivity to trazodone or any ingredient in the formulation.
Warnings and precautions
Potential for suicidal ideation/behaviour; QT prolongation and risk of arrhythmias; priapism; orthostatic hypotension; serotonin syndrome; abnormal bleeding risk with NSAIDs/anticoagulants.
Is TRAZODONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 19 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AX05 TRAZODONE. 21 of 57 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TRAZODONE | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537915 |
| AG-TRAZODONE | 150 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537923 |
| AG-TRAZODONE | 50 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537907 |
| APO-TRAZODONE D TABLETS 150MG | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02147653 |
| APO-TRAZODONE TABLETS 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02147645 |
| APO-TRAZODONE TABLETS 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02147637 |
| JAMP TRAZODONE | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442817 |
| JAMP TRAZODONE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442825 |
| JAMP TRAZODONE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442809 |
| PMS TRAZODONE HCL TAB 100MG | 100 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 01937235 |
Who else supplies TRAZODONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRAZODONE appears in 36 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.